Adherent cells from placenta and use of same in disease treatment

Abstract

Methods for treating conditions by administration of placenta derived adherent stromal cells to a subject in thereof are provided. Such conditions include skeletal muscle defects, neuropathic pain, and myocardial infarction. Also provided are methods wherein the adherent stromal cells administered are cultured under 2 dimensional or 3 dimensional growth conditions. Also provided are methods in which the cells administered are at least 70% adherent cells from a maternal or fetal portion of the placenta.

1 - 47 . (canceled) 
     
     
         48 . A method of treating heart failure in a subject in need thereof, the method comprising administering to said subject a composition comprising a population of adherent cells derived from a placenta, thereby treating the heart failure. 
     
     
         49 . The method of  claim 48 , wherein said adherent cells are less committed to differentiation into osteogenic lineages as compared to adherent cells from bone marrow grown and differentiated under the same conditions. 
     
     
         50 . The method of  claim 49 , wherein said adherent cells are less committed to differentiation into adipogenic lineages as compared to adherent cells from bone marrow grown and differentiated under the same conditions. 
     
     
         51 . The method of  claim 48 , wherein said adherent cells are less committed to differentiation into adipogenic lineages as compared to adherent cells from bone marrow grown and differentiated under the same conditions. 
     
     
         52 . The method of  claim 48 , wherein said adherent cells express one or more of CD73, CD90, CD29, CD105 or D7-fib. 
     
     
         53 . The method of  claim 48 , wherein said adherent cells do not express CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD14, CD19, CD34, CD31, CD200, KDR, or CD79. 
     
     
         54 . The method of  claim 48 , wherein said adherent cells express one or more of beta-Endorphin, dynorphin A, leu-enkephalin, or met-enkephalin. 
     
     
         55 . The method of  claim 48 , wherein the population comprises adherent cells from a maternal portion of the placenta. 
     
     
         56 . The method of  claim 48 , wherein the population comprises adherent cells from a fetal portion of the placenta. 
     
     
         57 . The method of  claim 48 , wherein the heart failure is antibody induced. 
     
     
         58 . The method of  claim 48 , wherein the heart failure is end stage. 
     
     
         59 . A method of treating cardiomyopathy in a subject in need thereof, the method comprising administering to said subject a composition comprising a population of adherent cells derived from a placenta, thereby treating the cardiomyopathy. 
     
     
         60 . The method of  claim 59 , wherein said adherent cells are less committed to differentiation into osteogenic lineages as compared to adherent cells from bone marrow grown and differentiated under the same conditions. 
     
     
         61 . The method of  claim 60 , wherein said adherent cells are less committed to differentiation into adipogenic lineages as compared to adherent cells from bone marrow grown and differentiated under the same conditions. 
     
     
         62 . The method of  claim 59 , wherein said adherent cells are less committed to differentiation into adipogenic lineages as compared to adherent cells from bone marrow grown and differentiated under the same conditions. 
     
     
         63 . The method of  claim 59 , wherein said adherent cells express one or more of CD73, CD90, CD29, CD105 or D7-fib. 
     
     
         64 . The method of  claim 59 , wherein said adherent cells do not express CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD14, CD19, CD34, CD31, CD200, KDR, or CD79. 
     
     
         65 . The method of  claim 59 , wherein said adherent cells express one or more of beta-Endorphin, dynorphin A, leu-enkephalin, or met-enkephalin. 
     
     
         66 . The method of  claim 59 , wherein the population comprises adherent cells from a maternal portion of the placenta. 
     
     
         67 . The method of  claim 59 , wherein the population comprises adherent cells from a fetal portion of the placenta.